47
Participants
Start Date
January 31, 2010
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Albuterol dry powder inhaler
Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
Teva Clinical Study Site, Minneapolis
Teva Clinical Study Site, Normal
Teva Clinical Study Site, Bellevue
Teva Clinical Study Site, Denver
Teva Clinical Study Site, Lakewood
Teva Clinical Study Site, Los Angeles
Teva Clinical Study Site, Los Angeles
Teva Clinical Study Site, Lake Oswego
Teva Clinical Study Site, North Dartmouth
Collaborators (1)
Parexel
INDUSTRY
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY